Wednesday, November 18, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Bayer’s Rally Faces a New Test: Antidumping Bid vs. Overbought Charts After Court Win

Rodolfo Hanigan by Rodolfo Hanigan
July 4, 2026
in Analysis, DAX, Pharma & Biotech
0
Bayer Stock
0
SHARES
97
VIEWS
Share on FacebookShare on Twitter

Just five days after a landmark Supreme Court victory, Bayer has opened a second front in its glyphosate saga — this time against Chinese imports. The stock has surged to within a whisker of its 52-week high, but traders are watching the charts with growing unease.

On 30 June 2026, Bayer’s Monsanto subsidiary and the newly created Ruveon LLC filed a petition with the US Department of Commerce and the International Trade Commission, seeking antidumping and countervailing duties on Chinese glyphosate. The move targets the price pressure from cheap Asian generic material that has eroded Bayer’s margins. The company — the last US-based manufacturer of the herbicide — had already forecast a 2% to 6% drop in glyphosate sales for 2026.

The petition landed less than a week after the US Supreme Court handed Bayer its biggest legal win in years. On 25 June, the justices ruled 7-2 in the Durnell case that the federal FIFRA statute pre-empts state-law claims over missing cancer warnings on glyphosate — provided the EPA has completed a final safety assessment. The decision overturned a $1.25 million verdict and effectively immunises Bayer from a wave of future lawsuits on that basis.

Rally Leaves the Stock Stretched

The market’s response has been electric. Bayer shares closed on Friday at €53.04, just 1.52% below the 52-week high of €53.86 set on 3 July. Over the past week, the stock has climbed 13.80%; over 30 days, it has soared 53.74%. Since the start of the year, the gain stands at 39.49%, and compared to the 52-week trough of €25.09 from August 2025, the stock has more than doubled — a 111.36% advance.

Yet the speed of the ascent has pushed technical readings into historically dangerous territory. The 14-day relative strength index stands at 85.1 — deep in overbought territory and well above the threshold where pullbacks typically occur. The stock now trades 36.50% above its 50-day moving average of €38.86 and 42.91% above the 200-day line of €37.11. The annualised 30-day volatility has spiked to 63.19%, underscoring the nervousness beneath the surface.

The Missing Piece: Settlement Approval Still Pending

For all the euphoria, the legal picture remains incomplete. The multibillion-dollar class-action settlement that would put the glyphosate litigation to rest has not yet been granted final approval. A Missouri court hearing initially set for early July has been postponed to 19 August 2026. Even after that date, appeals could drag on for years, as Bayer acknowledged in its own quarterly report.

Should investors sell immediately? Or is it worth buying Bayer?

Moreover, critics are already questioning the fairness of the deal, with some arguing that high attorneys’ fees could come at the expense of the affected plaintiffs. For the roughly 60,000 to 65,000 pending cases, the Supreme Court ruling weakens the legal foundation of future claims, but it does not extinguish current ones.

A Second Catalyst in the Pipeline

Bayer is not relying solely on litigation and trade action. On the pharmaceutical side, the US Food and Drug Administration is reviewing the stroke-prevention drug asundexian under an accelerated process. The company expects results in the second half of 2026 — a potential catalyst that could shift the narrative beyond glyphosate.

Still, the near-term outlook is dominated by the same question: Has the market already priced in the full benefit of the Supreme Court win before the settlement is even finalised? The antidumping petition adds another layer of uncertainty — it is unclear whether the US will open an investigation at all, let alone impose duties that meaningfully affect Bayer’s bottom line.

Chart Support and the August Hearing

With the RSI at such extreme levels, a consolidation phase looks likely. Short-term corrections are common after rallies of this magnitude, irrespective of the fundamental news flow. Should the stock retreat, the 50-day moving average near €39 is viewed as the first logical support zone. A hold above that level would suggest the re-rating is structurally sound.

The next concrete event remains the 19 August hearing in Missouri. Any fresh objections from plaintiffs’ lawyers or delays in the trade petition could puncture the rally. Conversely, a clean approval combined with progress on the China front could give the market reason to push the revaluation further.

For now, Bayer’s stock is caught between a historic legal victory and an overbought technical condition — with a new trade battle just getting started.

Ad

Bayer Stock: Buy or Sell?! New Bayer Analysis from November 18 delivers the answer:

The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 18.

Bayer: Buy or sell? Read more here...

Tags: Bayer
Rodolfo Hanigan

Rodolfo Hanigan

Related Posts

Rheinmetall Stock
DAX

Rheinmetall’s Order Book Pushes Past €80 Billion as New Shell Deal Lands

September 14, 2026
Commerzbank Stock
Banking & Insurance

Commerzbank’s CEO Puts a Price on Her Future as UniCredit Circles Closer

September 7, 2026
SAP Stock
Analysis

SAP’s Buyback Machine Grinds On, But the Analyst Chorus Is Turning Sour

September 7, 2026
Next Post
Nvidia Stock

Nvidia Tightens Its Grip on AI Infrastructure With a $500 Billion Backlog and a New Financing Model

Xiaomi Stock

For Xiaomi, the Memory-Chip Hangover Outweighs the EV Buzz

FALLBACK Stock

German Workers Losing Faith in Retirement as Coalition Tightens Sick-Leave Rules

Recommended

aTyr Pharma Stock

Make or Break Moment Approaches for aTyr Pharma

1 year ago
Battalion Oil Stock

Battalion Oil: Record-Breaking Wells in the Permian, But a Shelf Filing Casts a Long Shadow

7 months ago
IonQ Stock

IonQ Posts 755% Q1 Revenue Jump as Quantum Security Product Hits the Market

5 months ago
Stryker Stock

Analyst Confidence and Insider Activity Signal Strength for Stryker

10 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

The AI Rebound Gets an Audit: Who Earns, Who Borrows

A Hot CPI Reading Stalls the Rebound and Puts a December Hike in Play

Cash Over Stories: Take-Two, Cisco and Nvidia Face Their Tests

Trending

Nvidia Stock
Newsletter

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

by Stephanie Dugan
November 18, 2026
0

Dear readers, Nvidia reported the best quarter in its history, according to the company, and the founder...

Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026
Bitcoin Stock

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

November 16, 2026
Cisco Stock

At 5.15%, the 10-Year Treasury Picks the Winners

November 14, 2026
Bitcoin Stock

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

November 13, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone
  • Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers
  • Rotation, Not Panic: Retailers Test Where Tech’s Money Went

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com